» Articles » PMID: 38543085

Implications of NLRP3 Suppression Using Glibenclamide and MiR-223 Against Colorectal Cancer

Overview
Publisher MDPI
Specialty Chemistry
Date 2024 Mar 28
PMID 38543085
Authors
Affiliations
Soon will be listed here.
Abstract

The NLR family pyrin domain containing 3 (NLRP3) promotes the growth of colorectal cancer (CRC). However, the therapeutic effect of NLRP3 inhibition on CRC cell progression is controversial. This study comparatively investigated the therapeutic effect of a pharmacological NLRP3 inhibitor, glibenclamide (gli), and the post-translational suppression of NLRP3 by miR-223 on CRC cell progression in HCT-116 and HCT-15 cells. LPS and ATP were used to activate Gli-treated and LSB-hsa-miR-223-3p (WT)-expressing HCT-116 cells. NLRP3.AB.pCCL.sin.cPPT.U6.miR-223-Decoy.hPGK.GFP.WPRE plasmid (D) was the negative control for miR-223 expression. NLRP3, gasdermin D, and BAX expressions were analyzed using western blotting. Real-time PCR detected the RNA expression of autophagy-related genes ATG5, BECN1, and miR-223 in non-transfected cells. ELISA analyzed IL-1β and IL-18 in the medium. MTS-1, annexin V, wound-healing, and sphere-invasion assays were used to assess cell viability and progression. A multiplex cytokine assay detected proinflammatory cytokine secretion. LPS-ATP-activated NLRP3 produced gasdermin D cleavage, released IL-1b and IL-18, and activated cell migration and sphere invasion. In contrast, reduced cell growth, miR-223 expression, IFN-γ, CXCL10, and LIF secretion were found in cells after inflammasome activation. Both gli and WT induced autophagy genes ATG5 and BECN1 and reduced the NLRP3 activation and its downstream proteins. However, while gli had a limited effect on the production of IFN-γ, CXCL10, and LIF, WTmiR-223 increased the release of those cytokines. In addition, gli did not suppress cell growth, while WTmiR-223 promoted apoptosis. Notably, neither gli nor WTmiR-223 effectively prevented sphere invasion. These data suggest that, while WT could have a better anticancer effect in CRC compared to gli, the sole usage of miR-223-mediated NLRP3 suppression may not be sufficient to prevent CRC metastasis.

Citing Articles

Anti-Diabetic Therapies and Cancer: From Bench to Bedside.

Kounatidis D, Vallianou N, Karampela I, Rebelos E, Kouveletsou M, Dalopoulos V Biomolecules. 2024; 14(11).

PMID: 39595655 PMC: 11591849. DOI: 10.3390/biom14111479.


Inflammasomes Are Influenced by Epigenetic and Autophagy Mechanisms in Colorectal Cancer Signaling.

Muzes G, Sipos F Int J Mol Sci. 2024; 25(11).

PMID: 38892354 PMC: 11173330. DOI: 10.3390/ijms25116167.

References
1.
Krek A, Grun D, Poy M, Wolf R, Rosenberg L, Epstein E . Combinatorial microRNA target predictions. Nat Genet. 2005; 37(5):495-500. DOI: 10.1038/ng1536. View

2.
Monami M, Balzi D, Lamanna C, Barchielli A, Masotti G, Buiatti E . Are sulphonylureas all the same? A cohort study on cardiovascular and cancer-related mortality. Diabetes Metab Res Rev. 2007; 23(6):479-84. DOI: 10.1002/dmrr.736. View

3.
Xu S, Li X, Liu Y, Xia Y, Chang R, Zhang C . Inflammasome inhibitors: promising therapeutic approaches against cancer. J Hematol Oncol. 2019; 12(1):64. PMC: 6595574. DOI: 10.1186/s13045-019-0755-0. View

4.
Zahid A, Li B, Kombe Kombe A, Jin T, Tao J . Pharmacological Inhibitors of the NLRP3 Inflammasome. Front Immunol. 2019; 10:2538. PMC: 6842943. DOI: 10.3389/fimmu.2019.02538. View

5.
Dupaul-Chicoine J, Arabzadeh A, Dagenais M, Douglas T, Champagne C, Morizot A . The Nlrp3 Inflammasome Suppresses Colorectal Cancer Metastatic Growth in the Liver by Promoting Natural Killer Cell Tumoricidal Activity. Immunity. 2015; 43(4):751-63. DOI: 10.1016/j.immuni.2015.08.013. View